Ciregia, F, Kollipara, L, Giusti, L et al. · Translational psychiatry · 2016 · DOI
This study looked at proteins in the mitochondria—the energy-producing structures in cells—to see if they differ in people with ME/CFS compared to healthy people. Researchers found that two specific proteins (ATPB and ACON) were higher in people with ME/CFS, suggesting these could potentially be useful markers to help identify the condition. The findings also hint that different subgroups of ME/CFS patients may have different protein patterns, which could eventually lead to more personalized treatments.
This work contributes to growing evidence that mitochondrial dysfunction may underlie ME/CFS pathophysiology, offering potential diagnostic biomarkers that are noninvasive (saliva-based). The observation that different CFS patients show different protein patterns supports the emerging concept that ME/CFS comprises biologically distinct subgroups, which could enable future stratified diagnosis and targeted treatment development.
This study does not prove that elevated ATPB and ACON cause ME/CFS or that these proteins are causally linked to fatigue generation—correlation and mechanism remain unknown. It also does not establish whether these proteins represent a stable diagnostic marker across time, different tissues, or disease stages. The study cannot determine clinical utility for diagnosis without prospective validation and receiver-operating-characteristic analysis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →